European Journal of Cancer最新文献

{"title":"Is intraoperative ultrasonography a reliable method for surgical margin assessment?","authors":"B. Celik , S. Toprak , O. Agcaoglu , E. Dilege","doi":"10.1016/j.ejca.2026.116290","DOIUrl":"10.1016/j.ejca.2026.116290","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116290"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147554578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized non-inferiority trial comparing intraoperative versus postoperative radiotherapy after breast-conserving surgery in HER2-positive breast cancer with pathological complete response to neoadjuvant chemotherapy (IORTHER trial)","authors":"Y.A. Martínez Mateo , C. Casares Merino , M. Gómez Incio , I. Revollo Revollo , Á. García Aparicio , J.M. Ordiales Solís","doi":"10.1016/j.ejca.2026.116292","DOIUrl":"10.1016/j.ejca.2026.116292","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116292"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147554580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the reach and educational impact of a public oncology webinar series in South Africa: A model for accessible cancer education","authors":"C. Benn , D. Van Loggerenberg , T. Volschenk","doi":"10.1016/j.ejca.2026.116378","DOIUrl":"10.1016/j.ejca.2026.116378","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116378"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147538000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychosocial factors associated with return-to-work in breast cancer survivors","authors":"V. Voskanyan , F. Borgogni , C. Marzorati , G. Pravettoni","doi":"10.1016/j.ejca.2026.116366","DOIUrl":"10.1016/j.ejca.2026.116366","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116366"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147544866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Perspective among patients, caregivers and healthcare professionals (BCAP) - A qualitative study","authors":"B. Yadav , D. Kalsi , K. Sharma , A. Kajla , D. Dahiya","doi":"10.1016/j.ejca.2026.116369","DOIUrl":"10.1016/j.ejca.2026.116369","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116369"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147544922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LORIS: A multicentre, randomised phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ (DCIS): 5 year follow up. ISRCTN: 27544579. Currently in long term follow up. Sponsor: University Birmingham","authors":"M.G. Wallis , J. van de Wiel , P. Fairbrother , D. Rea , the LORIS TMG and Investigators","doi":"10.1016/j.ejca.2026.116309","DOIUrl":"10.1016/j.ejca.2026.116309","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116309"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147554624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors for one versus two pregnancies associated breast cancer","authors":"M. Izquierdo , S. Baulies , M. Gallardo , F. Fargas , C. Ara , F. Tresserra , R. Fabregas , P. Barri S","doi":"10.1016/j.ejca.2026.116329","DOIUrl":"10.1016/j.ejca.2026.116329","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116329"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147538729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study","authors":"Maria Gemelli ,&nbsp;Luca Sala ,&nbsp;Alessandro Morabito ,&nbsp;Vincenzo Sforza ,&nbsp;Alessio Cortellini ,&nbsp;Giulia La Cava ,&nbsp;Federica Bertolini ,&nbsp;Giorgia Guaitoli ,&nbsp;Simona Carnio ,&nbsp;Silvia Novello ,&nbsp;Alessandro Leonetti ,&nbsp;Marcello Tiseo ,&nbsp;Francesca Mazzoni ,&nbsp;Federica Cosso ,&nbsp;Marianna Macerelli ,&nbsp;Alexandro Membrino ,&nbsp;Giulio Metro ,&nbsp;Rita Chiari ,&nbsp;Carlo Genova ,&nbsp;Rossana Berardi ,&nbsp;Diego Luigi Cortinovis","doi":"10.1016/j.ejca.2026.116579","DOIUrl":"10.1016/j.ejca.2026.116579","url":null,"abstract":"<div><h3>Background</h3><div>The optimal duration of immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) remains undefined. While most trials adopt a 2-year treatment cap, evidence supporting this strategy in real-world practice is limited. The I-STOP study evaluated outcomes of patients with advanced NSCLC who achieved disease control after 24 months of ICI therapy and either discontinued or continued treatment.</div></div><div><h3>Methods</h3><div>I-STOP is a multicenter, observational study including patients with advanced NSCLC treated with single-agent PD-1/PD-L1 inhibitors for ≥ 24 months in 12 Italian institutions. Patients with complete response, partial response, or stable disease at 24 months were categorized according to treatment discontinuation. Progression-free survival (PFS) and overall survival (OS) were compared using 24-month landmark analyses; prognostic factors were assessed through Cox models.</div></div><div><h3>Results</h3><div>Among 173 eligible patients (median follow-up 55.4 months), 28 (16.2 %) discontinued ICI therapy at 24 months. Median OS was not reached in either cohort, with no difference between discontinuation and continuation groups (HR 1.22, 95 % CI 0.50–2.95; p = 0.66). Median PFS was 35.6 months in the discontinuation group versus not reached in the continuation group (HR 2.16, 95 % CI 1.04–4.48; p = 0.035). Higher progression risk after discontinuation was observed in patients with PD-L1 ≤ 50 %, brain metastases, ECOG PS ≥ 1, or KRAS mutations. Rechallenge achieved a 62.5 % response rate, and late grade 3–4 immune-related events were uncommon (3.5 %).</div></div><div><h3>Conclusions</h3><div>Discontinuing ICIs at 24 months appears to be a safe strategy for patients with durable disease control, without compromising survival outcomes. Nonetheless, some subgroups may benefit from continued treatment. Larger prospective studies are needed to identify which patients could gain from prolonged immunotherapy.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116579"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147283270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term cervical cancer risk following negative hrHPV-based versus negative cytology-based screening: A population-based study","authors":"Veerle J.C. Schevenhoven ,&nbsp;Erik E.L. Jansen ,&nbsp;Albert G. Siebers ,&nbsp;Inge M.C.M. de Kok","doi":"10.1016/j.ejca.2026.116601","DOIUrl":"10.1016/j.ejca.2026.116601","url":null,"abstract":"<div><h3>Background</h3><div>Randomized trials have shown that hrHPV-testing provides better protection against cervical cancer than cytology. However, long-term assessment of programme sensitivity remains essential. In the Netherlands, hrHPV-screening replaced cytology in 2017. We estimated the long-term cervical cancer risk following negative results in hrHPV- versus cytology-based screening.</div></div><div><h3>Methods</h3><div>Screening and histology data from the nationwide Dutch pathology databank (Palga) were used to identify 469,116 women without referral in 2014 (cytology-based) and 362,128 in 2017 (hrHPV-based), representing 4,071,690 person-years. Cervical cancer risk following non-referral, including interval cancers (IC) and those detected in the next screening round were analysed.</div></div><div><h3>Findings</h3><div>The incidence rate per 100,000 person-years was 3.3 IC following non-referral in cytology-based versus 2.7 following non-referral in hrHPV-based screening. Including next-round cancers, these numbers increase to 5.7 and 4.5. HrHPV-test negative women had a 50 % lower IC risk compared to those with normal cytology (HR 0.5; 95 % CI: 0.3–0.8), and 60 % lower when including next-round cancers (HR 0.4; 95 % CI: 0.3–0.5). HrHPV-positive women without referral had the highest cancer risk: 24 IC per 100,000 person-years, rising to 45 when including next-round cancers. Their risk was 3.4 times higher than for women with positive primary cytology without referral (HR: 3.4; 95 % CI: 1.1–8.1 for IC and HR: 3.4; 95 % CI: 1.4–8.1 including next-round cancers).</div></div><div><h3>Interpretation</h3><div>A negative hrHPV test was linked to lower long-term risk of cervical cancer than normal cytology, supporting longer screening intervals for hrHPV-negative women. However, hrHPV-positivity with negative cytology was associated with increased risk, suggesting the possible need for alternative triage guidelines.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116601"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late adverse effects after breastcancer (treatment) a survey study has proven our hypothesis that late adverse effects of breastcancer(treatment) can hinder quality of life. There's too little attention in consultation rooms; patients should be information about possible effects before the start of their treatment. Knowledge about late adverse effects, such as those of new treatments, is also needed. We want to raise awareness among patients, professionals, researchers and policymakers","authors":"A. Arps ,&nbsp;C. Guerrero Paez","doi":"10.1016/j.ejca.2026.116325","DOIUrl":"10.1016/j.ejca.2026.116325","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116325"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147537644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}